Filing Flows › Adma Biologics (ADMA) › Q1 2025
Adma Biologics (ADMA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
Adma Biologics (ADMA) reported revenue of $115M for the first quarter 2025 (Q1 2025), +40% from a year earlier and -2% from the quarter before. Operating margin was 30.4%, net earnings $26.9M (23.4% of revenue).
Adma Biologics, Q1 2025: revenue $115M (+40% year over year), operating margin 30.4%, net earnings $26.9M, operating cash flow −$19.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $115M | -2% | +40% |
| Gross profit | $61.1M | -4% | +56% |
| Operating profit | $34.9M | -9% | +60% |
| Net earnings | $26.9M | -76% | +51% |
| Operating cash flow | −$19.7M | — | — |
What changed
Revenue was $114.8M in Q1 2025, up 40% year over year and down 2% from the previous quarter.
Gross margin was 53.2%, up 5.5 points from a year earlier. Operating profit was $34.9M, a 30.4% margin (up 3.7 points year over year). Of the extra revenue versus a year earlier, 40% reached operating profit, above the 27% margin then. Operating expenses grew 52% against revenue growth of 40%. The fastest-growing cost line was Research & development (+84%). Net earnings were $26.9M, up 51% year over year. The effective tax rate was 19.6%.
Operating cash flow was −$19.7M. Non-cash charges added back $1.9M of depreciation and amortization and $4.6M of share-based compensation. Working capital and other items used $53.1M. Capital expenditures of $4.7M exceeded it, leaving free cash flow of −$24.4M.
Questions
What was Adma Biologics' revenue in the first quarter 2025?
Adma Biologics (ADMA) reported revenue of $115M for the first quarter 2025 (Q1 2025), +40% from a year earlier and -2% from the quarter before.
Was Adma Biologics profitable in the first quarter 2025?
Operating profit was $34.9M (30.4% of revenue) and net earnings $26.9M.
Source: Adma Biologics 10-Q on SEC EDGAR.